PM GatiShakti: 94th meeting held with evaluation of key infrastructure plans (See 'Corp Brief') ESIC Sanath Nagar Campus Recognized for Excellence in Public Healthcare (See 'Corp Brief') Shivraj Singh Chauhan announces formal end of 'Viksit Krishi Sankalp Abhiyan' and congratulated all scientists for their remarkable participation in campaign (See 'Corp Brief') PMLA - Interesting yet embarrassing question - Authority u/s 5 does not act as a Police force or Central Agency akin to a police force while passing an order of provisional attachment - Bench has jurisdiction to entertain petition: HC (See 'Legal Desk') Government of Assam presented Srimanta Sankardeva Award to renowned Indian classical dancer Dr Sonal Mansingh (See 'Corp Brief') Union Minister Manohar Lal reviewed implementation & progress of key urban development initiatives and infrastructure projects (See 'Corp Brief') Capital Market - Purchased plot being in settlement zone area, cannot be presumed to be agricultural land, and hence purchase of such settlement land is not contravention of FEMA Regulations: SAFEMA (See 'Legal Desk') Labour Ministry drives transformation in Social Security and Welfare (See 'Corp Brief') India, Norway discuss Blue Economy at UN Ocean Conference (See 'Corp Brief') IPR - Even though similarity in two competing trademarks cannot be ascertained by dissecting and comparing their parts, 'dominant parts' of trademarks can be compared: HC (See 'Legal Desk') 15-day Viksit Krishi Sankalp Abhiyan will conclude today (See 'Corp Brief') Union Minister to inaugurate Inland Fisheries and Aquaculture Meet 2025 (See 'Corp Brief') SARFAESI - If borrowers have already availed of remedy u/s 17 and secured creditor has no other alternative remedy, then creditor can avail remedy of petition under Article 227 of Constitution: HC (See 'Legal Desk') CCI approves acquisition of equity of Goldi Solar by Havells India (See 'Corp Brief') CCI okays acquisition of equity in Kolte-Patil Developers by BREP Asia III India Holding (See 'Corp Brief') India believes in science that is empathetic, ethical, and equitable: Pradhan (See 'Corp Brief') A&C - Subsequent revision of original menu by IRCTC form part of 'original contract containing arbitration clause' or not, is matter to be decided by Arbitrator: HC (See 'Legal Desk') Rs 244 crore sanctioned to boost Sustainable Tourism: Sonowal (See 'Corp Brief') BRIC-THSTI hosts symposium on 'Development of monoclonal antibody therapeutics' (See 'Corp Brief') Capital Market - Penalty for contravention of FERA provisions, shall be levied after adjustment of confiscated amount has been allowed looking to availability of cash in hand in cash-books of Firm: SAFEMA (See 'Legal Desk') India pushes for stronger Global Ocean Cooperation at UN Conference (See 'Corp Brief') FTII extends application deadline for Film Appreciation Course (See 'Corp Brief') IPR - Patent expiration does not eliminate company’s right to challenge biosimilar regulatory compliance: HC (See 'Legal Desk') QCI celebrates Role of Accreditation in empowering SMEs (See 'Corp Brief') Union Minister inaugurates NeVA Digital Platform for Puducherry Assembly (See 'Corp Brief') IPR - 'Complete Specification' of invention is sacrosanct for determining infringement of its patent: HC (See 'Legal Desk') World today looks up to India to overcome global challenges: MoS (See 'Corp Brief') Competition Law - Google imposing unfair conditions through agreements such as Television App Distribution Agreement and Android Compatibility Commitments, violates provisions of Competition Act, 2002: CCI (See 'Legal Desk') World Food Safety Day: Call for Innovations in Food Safety (See 'Corp Brief') IPR - Unauthorised use of 'AQUA' marks by defendants being deliberate, unjustified, and intended solely to capitalise on plaintiff's established goodwill, calls for damages: HC (See 'Legal Desk') Dr PK Mishra backs UN Chief on declaring heatwave global crisis (See 'Corp Brief') A&C - While Court may be guided by Orders XXXVIII and XXIX of CPC, decision in application u/s 9 is not strictly restrained by Order XXXVIII Rule 5: HC (See 'Legal Desk') MoS goes to France to attend International Meet on Oceans (See 'Corp Brief') PMLA - Attachment of property does not amount to its confiscation, as attachment under PMLA does not alter position with regard to ownership or even possession/use of properties: SAFEMA (See 'Legal Desk')

Print

BRIC-THSTI hosts symposium on 'Development of monoclonal antibody therapeutics'

Published: Jun 11, 2025

By TIOLCorplaws News Service

NEW DELHI, JUNE 11, 2025: TRANSLATIONAL Health Science and Technology Institute (THSTI) hosted a symposium on the Discovery and Development of Monoclonal Antibody Therapeutics yesterday at its campus. This event brought together leading experts from the pharmaceutical industry, start-ups, CRDMOs, various funding organizations (such as BIRAC, Wadhwani Foundation), and academic organizations for scientific knowledge exchange and to explore innovative models for advancing monoclonal antibody (mAb) therapies in India.

The symposium underscored India's burgeoning biopharmaceutical sector and the immense potential for indigenous innovation in this critical area. A key highlight of the discussions was the urgent need for enhanced collaboration between industry and academia, starting from the earliest stages of innovation and discovery, to develop affordable and indigenous technologies.

In his welcome address, Prof. Jayanta Bhattacharya, Dean, THSTI, emphasized the critical importance of early collaboration between industry and academia at the innovation and discovery stage. He highlighted that such partnerships are vital for developing indigenous and affordable technologies, which can significantly benefit the nation.

Prof. G. Karthikeyan, Executive Director, THSTI, further elaborated on India's significant contributions to the field of monoclonal antibodies. He noted that the current moment is critical, with supportive policies in place. Prof. Karthikeyan stressed the imperative to establish clusters where academia and industry can converge and collaborate. He said that these clusters would serve as fertile ground for training skilled personnel and that symposia like this are instrumental in uniting professionals from diverse sectors.

Dr. Alka Sharma,Scientist H and Senior Adviser, DBT, in her address, brought attention to the Bio-E3 policy (Biotechnology for Economy, Environment & Employment) of DBT, Government of India, detailing its key components. She underscored the pivotal role of mAbs in precision medicine and reaffirmed DBT's full commitment to their development. The Bio-E3 Initiative aims to catalyze biotechnological self-reliance by investing in advanced platforms like mAbs to combat diseases and strengthen local research and development capacity, reducing reliance on imports and ensuring equitable access to high-quality biologics.

The symposium featured a series of insightful presentations by representatives from various industry players actively engaged in monoclonal antibody research and development. Key sessions included:

- Novel mAb Discovery Platforms: Discussions included "Novel monoclonal antibody discovery by B-Cell Cloning" by Prof. Jayanta Bhattacharya (THSTI), "Novel biologics product development using next generation antibody engineering" by Dr. Maloy Ghosh (Zumutor Biologics), "Mammalian display as tool for antibody discovery" by Dr. KavitaKumari (Syngene International Ltd), and "Fit to Purpose tools for discovery of Antibodies" by Dr. Rakesh Kumar (Aragen Life Sciences).

- Development of Novel mAbs: This session explored topics such as "Antibody Architecture: Guiding Development Pathways and Assessing Manufacturability" by Dr. Priyaranjan Pattanaik (Aurigene Pharmaceutical Services Limited), and "Use of immunization techniques for getting correct immune response leading successful fit for purpose antibody discovery" by Dr. Sridhara Chakraborthy (Syngene International Ltd). Dr. SarikaMehra from IIT-Bombay also presented on "Combining directed evolution with multi-omics analysis to develop a high secretory CHO host cell line." Dr Saurabh Joshi from SPARC shared research insights on "antibody drug conjugates."

- New Horizons in mAbs: The symposium also delved into cutting-edge advancements with presentations like "A New Era in Biologics: Harnessing Circular RNA to Democratize mAb Access" by Dr. Anand Khedkar (Sekkei Bio Pvt Ltd) and "Where Efficiency Meets Innovation: AI-Driven Antibody Drug Design" by Dr. Aridni Shah (Immunito AI).

The symposium concluded with a panel discussion on "Accelerating Discovery and Early Development of Indigenous Therapeutic Solutions using Monoclonal Antibodies under Bio-E3 initiative," further solidifying the collaborative spirit. The panelists discussed ways to bring more funding to academia-industry collaborations and the need to have more such matchmaking sessions. These efforts are expected to lead to an expanded pipeline of mAb therapies, improved quality of learning and workforce preparation, and ultimately, drive economic growth and social progress.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.